Le Lézard
Classified in: Health, Covid-19 virus
Subject: PVP

THE WELL TOLD COMPANY COMPLETES FINAL CLOSING OF PRIVATE PLACEMENT


TORONTO, Sept. 20, 2022 /CNW/ - The Well Told Company Inc. ("Well Told" or ?the "Company") (TSXV: WLCO) (FSE: 7HO), the female-founded wellness company that offers plant-?based supplements, remedies, and other functional wellness products, is pleased to announce the final closing of the Company's non-brokered private placement (the "Offering"), previously announced on September 9, 2022. The Company has closed on the subscription announced on September 9, 2022 for an additional 1,000,000 units (a "Unit" or "Units") of the Company at $0.05 per ?Unit for gross proceeds of $50,000, which brings the total Offering to $706,250 through the issuance of 14,125,000 Units. Full details of the Offering can be found in the September 9, 2022 press release. The net proceeds of the Offering will be used by the Company for working capital.? All securities issued pursuant to the Offering are subject to a Canadian four-month hold period from the date of issuance, and may not be resold in the United States except in compliance with applicable U.S. ?securities laws.?

About The Well Told Company Inc.

Well Told is a female-founded, emerging plant-based wellness company that formulates, develops, distributes and sells a variety of supplements, remedies and other functional wellness products. Founded by serial entrepreneur and award-winning leader Monica Ruffo, it was after undergoing treatment for breast cancer, and deciding to take her health into her own hands that she discovered the lack of transparency and availability of clean, plant-based formulations in the wellness industry. With the mission "Clean wellness for all", Well Told's products are currently available in over 2,000 stores across Canada including several well-known retailers and recently launched in over 1,000 pharmacies in the U.S. in addition to being available at welltold.com, on Amazon, and in airports across the U.S.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered in the Offering have not been, and will not be, registered under the U.S. Securities ?Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the ?account or benefit of, United States persons absent registration or any applicable exemption from the ?registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This release ?shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor ?shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would ?be unlawful.?

Certain statements contained in this press release constitute "forward-looking information" ??as such term is defined in applicable Canadian securities legislation. The words "may", ???"would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", ???"estimate", "expect" and similar expressions as they relate to the Company, including: the use of the net proceeds of the Offering; are intended to ??identify forward-looking information. All statements other than statements of historical fact ??may be forward-looking information. Such statements reflect the Company's current views ??and intentions with respect to future events, and current information available to the ??Company, and are subject to certain risks, uncertainties and assumptions. Many factors could ?cause the actual results, performance or achievements ?that may be expressed or implied by ?such forward-looking information to vary from those ?described herein should one or more of ?these risks or uncertainties materialize. Examples of ?such risk factors include, without limitation: risks relating to credit, market (including equity, commodity, ?foreign exchange and interest ?rate), liquidity, operational, reputational, insurance, strategic, ?regulatory, legal, and ?environmental matters; the general business and economic conditions in the regions ?in which the Company operates; the ?ability of the Company to execute on key priorities; the ?Company's results of operations may ?be difficult to forecast; the Company is a holding ?company with its only asset being direct ?ownership of Well Told Inc.; the Company's success ?depends upon the continued strength of ?its reputation and brands; disruptions in ?manufacturing facilities or losses of site licenses and ?other qualifications could adversely ?affect sales and customer relationships; the Company's ?success depends on its ability to ?continue to enhance products and develop new products; the ?Company's suppliers and ?sources for materials and inputs may fail to support demand and ?increasing raw material ?costs could adversely affect margins; the Company is reliant on third ?parties for shipping and ?payment processing; the Company's ability to compete could be negatively impacted if it is ?unable to protect its intellectual property rights; the ability to implement business strategies ?and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the ?Company's information technology, internet, network access or ?other voice or data ?communications systems or services; the evolution of various types of ?fraud or other criminal ?behavior to which the Company is exposed; the failure of third par-?ties to comply with their ?obligations to the Company or its affiliates; the impact of new and ?changes to, or application ?of, current laws and regulations; granting of permits and licenses ?in a highly regulated ?business; the overall difficult litigation environment; increased competition; changes in ?foreign currency rates; increased funding costs and market volatility due to ?market illiquidity ?and competition for funding; the availability of funds and resources to pursue operations; ?critical accounting estimates and changes to accounting standards, policies, ?and methods ?used by the Company; the occurrence of natural and unnatural catastrophic ?events and ?claims resulting from such events; and risks related to COVID-19 including various ??recommendations, orders and measures of governmental authorities to try to limit the ??pandemic, including travel restrictions, border closures, non-essential business closures, ??quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, ??economic activity, financing, supply chains and sales channels, and a deterioration of general ??economic conditions including a possible national or global recession; as well as those risk ??factors discussed or referred to in the Company's disclosure documents filed with the ??securities regulatory authorities in certain provinces of Canada and available at ??www.sedar.com. Should any factor affect the Company in an unexpected manner, or should ??assumptions underlying the forward-looking information prove incorrect, the actual results ??or events may differ materially from the results or events predicted. Any such forward-??looking information is expressly qualified in its entirety by this cautionary statement. ??Moreover, the Company does not assume responsibility for the accuracy or completeness of ??such forward-looking information. The forward-looking information included in this press ??release is made as of the date of this press release and the Company undertakes no obligation ??to publicly update or revise any forward-looking information, other than as required by ??applicable law.?

SOURCE Well Told Inc.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: